Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/ajd.70012 http://scihub22266oqcxt.onion/10.1111/ajd.70012 41347368!?!41347368       Australas+J+Dermatol 2025 ; ? (?): ? Nephropedia Template TP {{tp|p=41347368|t=2025. Efficacy and Safety of Risankizumab in Psoriatic Patients With a History of Malignancy: Real-World Evidence From a Multicentre Spanish Study |pdf=|usr=}}{{41347368}} gab.com Text Efficacy and Safety of Risankizumab in Psoriatic Patients With a History of Malignancy: Real-World Evidence From a Multicentre Spanish Study JO: Australas J Dermatol http://www.kidney.de/pget.php?&tw=1&pmid=41347368 #FOAvip The management of psoriasis in patients with a history of malignancy is challenging. We conducted a multicentre, retrospective study in 17 Spanish centres including 69 patients with moderate-to-severe psoriasis and a previous or current malignancy treated with risankizumab; 94.2% of patients showed no recurrence or progression of cancer, while 5.8% experienced progression during therapy. Risankizumab was associated with substantial improvement in psoriasis, with a mean final PASI score of 0.9 +/- 1.7 after a mean exposure time of 72 weeks. Tolerance was favourable, and no tumour recurrence was considered treatment-related. These findings support risankizumab as an effective and safe therapeutic option for this subpopulation. Twit Text FOAVip Efficacy and Safety of Risankizumab in Psoriatic Patients With a History of Malignancy: Real-World Evidence From a Multicentre Spanish Study ????Australas J Dermatol http://www.kidney.de/pget.php?&tw=1&pmid=41347368 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=41347368 #FOAvip English Wikipedia <ref>{{Cite pmid|41347368}}</ref> Efficacy and Safety of Risankizumab in Psoriatic Patients With a History of Malignancy: Real-World Evidence From a Multicentre Spanish Study #MMPMID41347368 Diaz JM; Alarcon SS; Romero IB; Apetrei LS; Fernandez LG; Ramos FJM; Alberola FT; Martinez MAB; Ruiz AB; Rodriguez OB; Ruiz-Villaverde R; Gonzalez MC; Farres MF; Puchades AM; Tapial JM; Rull EV; Montalvo SM Australas J Dermatol 2025[Dec]; ? (?): ? PMID41347368show ga The management of psoriasis in patients with a history of malignancy is challenging. We conducted a multicentre, retrospective study in 17 Spanish centres including 69 patients with moderate-to-severe psoriasis and a previous or current malignancy treated with risankizumab; 94.2% of patients showed no recurrence or progression of cancer, while 5.8% experienced progression during therapy. Risankizumab was associated with substantial improvement in psoriasis, with a mean final PASI score of 0.9 +/- 1.7 after a mean exposure time of 72 weeks. Tolerance was favourable, and no tumour recurrence was considered treatment-related. These findings support risankizumab as an effective and safe therapeutic option for this subpopulation. ?Efficacy and Safety of Risankizumab in Psoriatic Patients With a Histo(epmc).pdf DeepDyve Pubget Overpricing